PTC Therapeutics has officially launched its Middle East and North Africa (MENA) office at Dubai Science Park, aiming to improve access to innovative medicines for patients suffering from rare diseases in the region. The new facility is part of PTC’s strategy to enhance its regional operations and deliver a growing portfolio of treatments tailored to rare disease patients.

The company specializes in developing and commercializing breakthrough therapies for rare diseases worldwide. With this new office, PTC plans to establish a regional hub that is focused on delivering effective solutions and improving health outcomes for patients across the MENA region.

Zeina Sfeir, Head of MENA at PTC Therapeutics, expressed enthusiasm about the new office, stating that they are eager to serve more patients with their diverse range of therapeutic areas and a strong commitment to patient care.

Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, emphasized the significance of the park’s ecosystem as a collaborative platform for researchers and healthcare professionals. He welcomed PTC Therapeutics as a partner in their mission to translate scientific advancements into effective therapies, contributing to initiatives like the Dubai Research and Development Programme and the Dubai Economic Agenda ‘D33’.

PTC Therapeutics has a history of nearly ten years in the region, where it has built strong partnerships with local stakeholders. The company has already made strides in enhancing patient outcomes for rare diseases, including providing transformative treatments for Duchenne Muscular Dystrophy (DMD) and a gene therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.